Transplant Diagnostic Market is Expected to Expand at a CAGR of 6.6% From 2018 to 2026

Press Release

The global transplant diagnostic market was valued at US$ 730.9 Mn in 2017 and is projected to expand at a cumulative annual growth rate (CAGR) of 6.6% from 2018 to 2026 according to a new report published by Transparency Market Research (TMR) titled “Transplant Diagnostic Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026” the report suggests that increase in number of cancer & blood disorder patients and rise in the demand for accurate and cost-effective transplant diagnostic systems is fueling the transplant diagnostic market between 2018 and 2026. North America and Europe are projected to dominate the global market owing to the increase in demand for efficient and effective management of transplant diagnostic technique and high adoption rate of transplant of organs.

The market in Asia Pacific is projected to expand at a prominent growth rate during the forecast period. Expansion of the market in Asia Pacific is attributed to the large base of hospital & transplant centers and research centers, rising number of geriatric population requiring kidney dialysis services, and increasing awareness regarding donation of organs among young generation in the region. The market for transplant diagnostic in Latin America is likely to expand at a moderate growth rate during the forecast period.

Request a Sample of Transplant Diagnostic Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20225

  • Non-molecular assay is projected to be highly lucrative deployment mode

Non-molecular assays are conventional methods of transplant diagnostic. These assays are employed in developed as well as developing countries in order to detect transplant rejections. Furthermore, these technology-based transplant diagnostic are priced on perpetual license model and are highly priced. Non-molecular assays enable the user to practice antibody-based histocompatibility test that offers low-resolution typing, as compared to molecular assays, and involve culturing together of lymphocytes. These factors are likely to propel the segment during the forecast period. These non-molecular assay-based techniques addresses specific challenges during identification of the molecules, which expresses on the cells and are involved in the immune rejection of mismatched grafts. The non-molecular assay-based techniques offer rapid results on transplantation and are cost-effective.

  • Key trend of research and development among the leading players to increase geographic presence has been observed in last few years

The report also provides profiles of leading players operating in the global transplant diagnostic market. Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., and Becton, Dickinson and Company are a few leading players operating in the global transplant diagnostic market, which account for significant market share. Companies operating in the transplant diagnostic industry are emphasizing on increasing their geographic presence by means of strategic acquisition and collaboration with leading players in respective domains and geography. In July 2017, Thermo Fisher Scientific acquired Linkage Biosciences.

This post was originally published on Analytics News